Chances/Challenges of the Role of New Beta-lactamase Inhibitors Against the Growing Threat of NDM-producing Escherichia coli With Penicillin-binding Protein 3 Mutations
- 23 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (4) , 925
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates ofAcinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2023
- Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)The Lancet Infectious Diseases, 2023
- Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic ReviewAntibiotics, 2022
- Dual β-lactam combination therapy for multi-drug resistant Pseudomonas aeruginosa infection: enhanced efficacy in vivo and comparison with monotherapies of penicillin-binding protein inhibitionScientific Reports, 2019
- ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumanniiNature Microbiology, 2017